Literature DB >> 3379139

Correlations of serum concentrations of 1,25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis.

K W Lyles1, D L Halsey, N E Friedman, B Lobaugh.   

Abstract

The inherited metabolic disorder tumoral calcinosis is characterized by elevated serum phosphorus and 1,25-dihydroxyvitamin D [1,25-(OH)2D] levels and paraarticular calcific tumors. The pathogenesis of this disease is obscure, but an elevated renal phosphate reabsorption threshold and increased production of 1,25-(OH)2D are postulated as defects. We studied nine affected patients and found that both serum phosphorus and renal phosphate reabsorption threshold (TmP/GFR) were positively correlated with serum 1,25-(OH)2D levels. Since tumoral calcinosis is a disorder with abnormal renal phosphate transport, we compared the TmP/GFR and serum 1,25-(OH)2D levels to values obtained in patients with two other diseases with renal phosphate transport defects: oncogenic osteomalacia and X-linked hypophosphatemic rickets. We found a significant correlation between TmP/GFR and 1,25-(OH)2D levels in all three diseases, suggesting that in these diseases 1,25-(OH)2D production is regulated in some manner by phosphate transport. Furthermore, previous work indicated that in tumoral calcinosis broad variation exists in serum phosphorus levels. In our patients a negative correlation was found between the serum PTH concentrations and both serum phosphorus levels and TmP/GFR values, respectively. We postulate that although the basic defect in tumoral calcinosis most likely resides in the proximal renal tubular cell, the variation in serum phosphorus levels and possibly disease expression is modulated in part by PTH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3379139     DOI: 10.1210/jcem-67-1-88

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Fibroblast growth factor 23 as a phosphotropic hormone and beyond.

Authors:  Seiji Fukumoto; Yuichiro Shimizu
Journal:  J Bone Miner Metab       Date:  2011-08-06       Impact factor: 2.626

2.  Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.

Authors:  Anuja Shah; Clinton J Miller; Cynthia C Nast; Mark D Adams; Barbara Truitt; John A Tayek; Lili Tong; Parag Mehtani; Francisco Monteon; John R Sedor; Erica L Clinkenbeard; Kenneth White; Rajnish Mehrotra; Janine LaPage; Patricia Dickson; Sharon G Adler; Sudha K Iyengar
Journal:  Nephrol Dial Transplant       Date:  2014-11-05       Impact factor: 5.992

3.  Tumoral calcinosis-like lesion of the proximal linea aspera.

Authors:  L L Seeger; D L Butler; J J Eckardt; L Layfield; J S Adams
Journal:  Skeletal Radiol       Date:  1990       Impact factor: 2.199

4.  Effects of estrogen on circulating "free" and total 1,25-dihydroxyvitamin D and on the parathyroid-vitamin D axis in postmenopausal women.

Authors:  C Cheema; B F Grant; R Marcus
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

5.  Tumoral calcinosis: a case report.

Authors:  J Prasad; S Malua; D K Sinha; F Hassan; R Tekriwal
Journal:  Indian J Surg       Date:  2008-01-28       Impact factor: 0.656

Review 6.  Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models.

Authors:  Nan Su; Min Jin; Lin Chen
Journal:  Bone Res       Date:  2014-04-29       Impact factor: 13.567

7.  Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism.

Authors:  Tasuku Saito; Seiji Fukumoto
Journal:  Int J Pediatr Endocrinol       Date:  2009-10-07

Review 8.  FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.

Authors:  Anna Kurpas; Karolina Supeł; Karolina Idzikowska; Marzenna Zielińska
Journal:  Dis Markers       Date:  2021-05-17       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.